Tech Company Financing Transactions
Tokai Pharmaceuticals Funding Round
Tokai Pharmaceuticals closed a $22 million Series D funding round on 5/8/2009. Backers included Novartis Venture Fund and Apple Tree Partners.
Transaction Overview
Company Name
Announced On
5/8/2009
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series D
Investors
Novartis Venture Fund (Lead Investor) (Reinhard Ambros)
Apple Tree Partners (Seth Harrison)
Proceeds Purpose
Proceeds from the financing will be used to advance Tokai's lead development candidate, TOK-001, into the clinic for the treatment of advanced prostate cancer.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
255 State St. 6th floor
Boston, MA 02109
USA
Boston, MA 02109
USA
Phone
Website
Email Address
Not Recorded
Overview
Tokai Pharmaceuticals (NASDAQ: TKAI) develops biopharmaceutical products that focus on endocrine treatment. The company is developing novel, proprietary therapies for prostate cancer and other hormonally-driven diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jodie Morrison
Chief Operating Officer
John McBride
Browse more venture capital transactions:
Prev: 5/7/2009: Foodista venture capital transaction
Next: 5/8/2009: Enphase Energy venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs